Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;36(10):977-982.
doi: 10.1038/nbt.4199. Epub 2018 Jul 30.

An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities

Affiliations

An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities

Jason M Gehrke et al. Nat Biotechnol. 2018 Nov.

Abstract

Base editor technology, which uses CRISPR-Cas9 to direct cytidine deaminase enzymatic activity to specific genomic loci, enables the highly efficient introduction of precise cytidine-to-thymidine DNA alterations. However, existing base editors create unwanted C-to-T alterations when more than one C is present in the enzyme's five-base-pair editing window. Here we describe a strategy for reducing bystander mutations using an engineered human APOBEC3A (eA3A) domain, which preferentially deaminates cytidines in specific motifs according to a TCR>TCY>VCN hierarchy. In direct comparisons with the widely used base editor 3 (BE3) fusion in human cells, our eA3A-BE3 fusion exhibits similar activities on cytidines in TC motifs but greatly reduced editing on cytidines in other sequence contexts. eA3A-BE3 corrects a human β-thalassemia promoter mutation with much higher (>40-fold) precision than BE3. We also demonstrate that eA3A-BE3 shows reduced mutation frequencies on known off-target sites of BE3, even when targeting promiscuous homopolymeric sites.

PubMed Disclaimer

Conflict of interest statement

COMPETING FINANCIAL INTERESTS STATEMENT

J.M.G. is currently a full-time employee of and holds equity in Beam Therapeutics. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Monitor Biotechnologies, Pairwise Plants, Poseida Therapeutics, and Transposagen Biopharmaceuticals. J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.M.G. and J.K.J. are inventors on a patent application that has been filed for engineered sequence-specific deaminase domains in base editor architectures.

Figures

Figure 1:
Figure 1:. Engineering and characterization of an A3A-BE3 base editor that selectively edits Cs preceded by a 5’ T.
(a) Schematic illustrating the architecture of the original BE3 fusion (consisting of rAPO1 linked to SpCas9 nickase and UGI) and the A3A-BE3 fusion. (b) Activities of BE3, A3A-BE3, and a series of A3A-BE3 variants bearing mutations in A3A on an integrated EGFP reporter gene target site bearing a cognate cytidine preceded by a 5’ T and a bystander cytidine preceded by a 5’ G in the editing window. Center values represent the mean of n = 3 biologically independent samples and error bars represent SEM .(c) Schematic summarizing specific and non-specific interactions between amino acid positions in A3A and its substrate single-stranded DNA derived from previously published co-crystal structures. (d) Heat maps showing C-to-T editing efficiencies for BE3, YE BE3s, and various A3A-BE3 variants at 12 endogenous human gene target sites, each bearing a cognate cytidine preceded by a 5’ T (indicated with a black arrow) and one or more bystander cytidines within the editing window. All editing efficiencies shown represent the mean of n = 3 biologically independent samples.
Figure 2:
Figure 2:. Off-target editing activities of BE3 and eA3A-BE3 variants.
On- and off-target editing frequencies of four gRNAs targeted to (a) EMX1 site 1, (b) VEGFA site 2, (c) FANCF site 1 or (d) CTNNB1 site 1 with BE3 or one of the indicated eA3A-BE3 variants. Percentage edits represent the sum of all edited Cs in the editing window and represent the mean of n = 3 biologically independent samples with error bars representing SEMs. Intended target sequence is shown at the top of each graph. On-target sites are marked with a black diamond to the left and mismatches or bulges in the various off-target sites are shown with colored boxes or a dash in gray boxes, respectively. Off-target sites that lose the cognate TC motif within the editing window and thus might be expected to show lower off-target editing by eA3A, are noted with empty circles to the left. Asterisks indicate statistically significant differences in editing efficiencies observed between BE3 and eA3A-BE3 at each site (* p < 0.05, ** p < 0.005, *** p < 0.0005). All statistical testing was performed using two-tailed Student’s t-test according to the method of Benjamini, Krieger, and Yekutieli without assuming equal variances between samples.
Figure 3:
Figure 3:. On- and off-target activities of eA3A-BE3 variants at a β-thalassemia-causing mutation HBB −28 (A>G) sequence in human cells.
(a) Schematic of the HBB −28 (A>G) mutation and potential base editing outcomes when targeting Cs at −28 and −25 in the editing window of an HBB-targeting gRNA. Mutations to the bystander cytidine at the −25 position are deleterious and cause β-thalassemia phenotypes independent of the identity of the −28 nucleotide. (b) Heat maps showing C-to-T editing efficiencies for BE3, YE BE3s, and various A3A-BE3 variants at the HBB −28 (A>G) target site in an integrated reporter in human HEK293T cells. The −28 C is indicated with a black arrow. Editing efficiencies shown represent the mean of n = 3 biologically independent samples. (c) Graph showing the frequencies of perfectly corrected (−28 C to T only) and other imperfectly edited (−28 C to G or other edited Cs) alleles by BE3, YE BE3 variants, and eA3A-BE3 variants. Efficiencies shown represent the mean of n = 3 biologically independent samples. (d) On- and off-target editing frequencies of the HBB-targeted gRNA with BE3, YE BE3 variants, or eA3A-BE3 variants. Percentage edits represent the sum of all edited Cs in the editing window and represent the mean of n = 3 biologically independent samples with error bars representing SEMs. Intended target sequence is shown at the top. On-target site is marked with a black diamond to the left and mismatches or bulges in the various off-target sites are shown with colored boxes or a dash in gray boxes, respectively. Off-target sites that lose the cognate TC motif within the editing window and thus might be expected to show lower off-target editing by eA3A, are noted with empty circles to the left. Asterisks indicate statistically significant differences in editing efficiencies observed between BE3 and eA3A-BE3 and between eA3A-BE3 and the untransfected control (* p < 0.05, ** p < 0.005, *** p < 0.0005). All statistical testing was performed using two-tailed Student’s t-test according to the method of Benjamini, Krieger, and Yekutieli without assuming equal variances between samples.

Comment in

  • Better base editors.
    Rusk N. Rusk N. Nat Methods. 2018 Oct;15(10):763. doi: 10.1038/s41592-018-0154-4. Nat Methods. 2018. PMID: 30275576 No abstract available.

References

    1. Komor AC, Kim YB, Packer MS, Zuris JA & Liu DR Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016). - PMC - PubMed
    1. Nishida K et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, (2016). - PubMed
    1. Kim K et al. Highly efficient RNA-guided base editing in mouse embryos. Nat. Biotechnol 35, 435–437 (2017). - PubMed
    1. Rees HA et al. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat. Commun 8, 15790 (2017). - PMC - PubMed
    1. Shimatani Z et al. Targeted base editing in rice and tomato using a CRISPR-Cas9 cytidine deaminase fusion. Nat. Biotechnol 35, 441–443 (2017). - PubMed

METHODS-ONLY REFERENCES

    1. Pinello L et al. Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol 34, 695–697 (2016). - PMC - PubMed
    1. Kulcsár PI et al. Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage. Genome Biol. 18, 190 (2017). - PMC - PubMed
    1. Kim S, Bae T, Hwang J & Kim J-S Rescue of high-specificity Cas9 variants using sgRNAs with matched 5’ nucleotides. Genome Biol. 18, 218 (2017). - PMC - PubMed
    1. Ye L et al. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia. Proc. Natl. Acad. Sci 113, 10661–10665 (2016). - PMC - PubMed

Publication types